New!
Product Code: 07-POCT-CYP2-26
From £1300.00
Registration closed: 18/09/2025
Point-of-care molecular testing (POCT) of CYP2C19 for optimisation of antiplatelet therapy (Artificial Buccal swabs)
CYP2C19 variants *2, *3, and *17
PCR based
Not applicable
Artificial Buccal Swab
No
Every 2 months
4 weeks after sample dispatch
The scheme is designed to assess the analytical process (genotyping) only.
The user will receive a survey report containing device specific performance data, benchmarked against the cohort of participating users. Additionally a annual report summarising the years data will also be provided.
Point-of-Care testing for CYP2C19 *2, *3, and *17 variants. Users will receive three EQA samples every two months (18 samples per year), allowing them to verify the ongoing accuracy of CYP2C19 testing on their POCT devices, to ensure patients receive the most reliable diagnoses possible.
Users are required to report CYP2C19 *2, *3, and *17 detection status, with additional patient identifiers.
Additional samples are available to purchase for device verification. You can purchase a verification package of materials from our website by navigating to the ‘Our EQA Schemes’ section, selecting ‘Buy an EQA Scheme,’ and searching for ‘DVS.’ No restrictions on number of participants. Open to laboratories from ALL countries (note: some restrictions may apply due to sanctions, delivery network exceptions, restrictions on importation etc).
added wishlist!
View Wishlist
View Wishlist
Express your interest in ''.
